Hepatitis C Virus Infection in Hemodialysis Patients in the Era of Direct-Acting Antiviral Treatment: Observational Study and Narrative Review

• Published in: Medicina (Kaunas, Lithuania) Lithuania), 2024-12, Vol.60 (12), p.2093
• Main Authors: Ratiu, Ioana Adela, Mihaescu, Adelina, Olariu, Nicu, Ratiu, Cristian Adrian, Bako, Gabriel Cristian, Ratiu, Anamaria, Indries, Mirela, Fratila, Simona, Dejeu, Danut, Teusdea, Alin, Ganea, Mariana, Moisa, Corina, Luciana, Marc
• Format: Article
• Language: English
• Subjects: Antibodies; Antigens; Asymptomatic; Collaboration; comorbidities; Diabetes; direct-acting antivirals (DAAs); Genotype & phenotype; Hemodialysis; Hepatitis C; hepatitis C virus; Immunoassay; Infections; Kidney diseases; Liver cancer; Liver cirrhosis; malignancies; Medical prognosis; Viral infections
• ISSN: 1010-660X; 1648-9144
• DOI: 10.3390/medicina60122093

Background and Objectives: Hepatitis C virus (HCV) infection is a major global public health concern, particularly in hemodialysis (HD) patients. This study aims to evaluate the demographic, clinical, and laboratory characteristics of HCV-positive patients undergoing HD and assess the long-term impact of direct-acting antivirals (DAAs) on patient outcomes. Moreover, a narrative review aims to summarize the current knowledge regarding HCV treatment in HD patients. The search in the PubMed, Google Scholar, and Scopus databases identified 48 studies relevant to our topic, 18 regarding clinical history and 29 related to HCV treatment. Methods: A retrospective analysis was performed on 165 HD patients from Bihor County HD centers, Romania, between 2014 and 2024. The cohort was divided into two groups: 54 patients who tested positive for HCV and 111 controls who were HCV-negative. Data collected from GPs included demographic information, comorbidities, laboratory parameters, and psychological assessments. Outcomes were evaluated at over 5 years after DAA treatment. A literature review was conducted using PubMed and Google Scholar to identify relevant studies on HCV in HD patients from 1989 to 2024. Results: Laboratory results showed similar parameters across groups, except for lower serum cholesterol levels in the HCV-positive DAA-treated group vs. HCV-positive non-treated ones (155.607 mg% vs. 170.174 mg%, p = 0.040) and increased ALT levels when comparing the same groups (29.107 vs. 22.261, p = 0.027), whereas comorbidities did not differ significantly. The incidence of malignancies was significantly higher among HCV-positive compared to HCV-negative patients (20.3% vs. 8.1%, p = 0.023), mainly among those treated with DAAs, highlighted by the multivariate analysis. Cardiovascular disease remains the leading cause of mortality regardless of HCV status or the use of antiviral therapy. Psychological assessments revealed more severe depression in HCV-positive patients compared to their HCV-negative counterparts. Conclusions: HCV infection in the hemodialysis population typically follows a subclinical course. At over five years after DAA therapy, the results indicate a stabilization of the liver function and the absence of major complications. However, the incidence of malignancies remains high in HCV-positive patients.